Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 111 (5), 1607-1618
- https://doi.org/10.1111/cas.14395
Abstract
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first-line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires resistance to sunitinib, rendering it difficult to treat with this agent. Recently, Rapalink-1, a drug that links rapamycin and the mTOR kinase inhibitor MLN0128, has been developed with excellent therapeutic effects against breast cancer cells carrying mTOR resistance mutations. The aim of the present study was to evaluate the in vitro and in vivo therapeutic efficacy of Rapalink-1 against renal cell carcinoma (RCC) compared to temsirolimus, which is commonly used as a small molecule inhibitor of mTOR and is a derivative of rapamycin. In comparison with temsirolimus, Rapalink-1 showed significantly greater effects against proliferation, migration, invasion and cFolony formation in sunitinib-naive RCC cells. Inhibition was achieved through suppression of the phosphorylation of substrates in the mTOR signal pathway, such as p70S6K, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and AKT. In addition, Rapalink-1 had greater tumor suppressive effects than temsirolimus against the sunitinib-resistant 786-o cell line (SU-R 786-o), which we had previously established, as well as 3 additional SU-R cell lines established here. RNA sequencing showed that Rapalink-1 suppressed not only the mTOR signaling pathway but also a part of the MAPK signaling pathway, the ErbB signaling pathway and ABC transporters that were associated with resistance to several drugs. Our study suggests the possibility of a new treatment option for patients with RCC that is either sunitinib-sensitive or sunitinib-resistant.Funding Information
- the KAKENHI (16H05464, 17H04332)
- the KAKENHI (17K16799)
- the KAKENHI (16K11015)
This publication has 49 references indexed in Scilit:
- Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer CellsMolecular Cancer Therapeutics, 2012
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell CarcinomaClinical Cancer Research, 2010
- Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling SymphonyOnline Journal of Public Health Informatics, 2010
- The genetic basis of kidney cancer: a metabolic diseaseNature Reviews Urology, 2010
- CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) ComplexOnline Journal of Public Health Informatics, 2009
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2Online Journal of Public Health Informatics, 2008
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences of the United States of America, 2008
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJCI Insight, 2008
- Hypoxia-inducible factors: central regulators of the tumor phenotypeCurrent Opinion in Genetics & Development, 2007
- Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor GrowthPLoS Biology, 2003